Yanwen Chen

Years Active: 2020-2024
Publications (10 Years): 5

University of Hong Kong (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Hong Kong Sep 01 2018

Hong Kong

PHD :: School of Biological Sciences

Sun Yat-Sen University Sep 01 2014 - Aug 31 2018

China

BSC :: School of Life Sciences

Publications

Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma (2024)
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert M Dean, Omer Koc, Kirsten Boughan, Brenda W Cooper, Brad Pohlman, Paolo F Caimi, Mitchell Reed Smith
Lenalidomide, rituximab (R 2 ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Leukemia & lymphoma 65 (6) (2024)
Bin-E Xue, Yanwen Chen, Richard M K Saunders
Phylogenetic relationships of 'Polyalthia' in Fiji. PhytoKeys 165 (2020)

Yanwen Chen.css-eqlu8i{font-size:small;padding-left:4px;}